Pampa Energía SA (PAM) Stock

Marvell Technology, Inc. has launched the Marvell® Ara, a new 3nm PAM4 interconnect platform that offers 1.6 Tbps and features 200 Gbps electrical and optical interfaces. This innovative technology reduces the power consumption of optical modules by 20%, which supports the widespread use of high-speed network infrastructure to meet the growing demands for AI bandwidth. The announcement was made on December 3, 2024, in Santa Clara, California.

Pampa Energia S.A. (NYSE:PAM) will hold its Q3 2024 Earnings Conference Call on November 7, 2024, at 10:00 AM ET. The call will feature company representatives, including Raquel Cardasz and Gustavo Mariani, along with various participants from financial institutions. Raquel Cardasz will begin the call by welcoming everyone and expressing gratitude for their patience.

At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. However, we also keep an eye on the most recent trends in value, growth, and momentum to support our top selections.

Is Pampa Energia (PAM) a strong choice for momentum investors? Let's investigate.

Neurosterix was launched in partnership with Perceptive Advisors to speed up the development of M4PAM for treating schizophrenia. Indivior has chosen a GABA B PAM drug candidate to work on substance use disorders, while Addex has picked an independent GABAB PAM drug candidate for chronic cough treatment. On September 30, 2024, Addex Therapeutics, a biopharmaceutical company focused on neurological disorders, shared its financial results for the first half of the year and gave a corporate update.

Pampa (PAM) could see an increase in value due to rising confidence in its earnings potential, as shown by its upgrade to a Zacks Rank #1 (Strong Buy).

Is Pampa Energia (PAM) a strong choice for momentum investors? Let's take a closer look.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today.